Follow-on Biologics Get Modest Savings Score From CBO, Giving Legislation No Push

Congressional Budget Office projects follow-on products could capture 35 percent of market with 40 percent lower price tag.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet